IQVIA (NYSE:IQV - Get Free Report) issued its quarterly earnings results on Tuesday. The medical research company reported $2.81 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.77 by $0.04, Briefing.com reports. IQVIA had a return on equity of 30.05% and a net margin of 7.88%. The business had revenue of $4.02 billion for the quarter, compared to analyst estimates of $3.96 billion. During the same quarter in the prior year, the firm posted $2.64 earnings per share. The firm's revenue for the quarter was up 5.3% compared to the same quarter last year. IQVIA updated its FY 2025 guidance to 11.750-12.050 EPS.
IQVIA Price Performance
NYSE IQV traded down $3.95 during midday trading on Friday, hitting $196.87. The company had a trading volume of 871,123 shares, compared to its average volume of 2,034,289. The company has a market capitalization of $33.47 billion, a PE ratio of 28.47, a P/E/G ratio of 2.29 and a beta of 1.30. The company has a current ratio of 0.84, a quick ratio of 0.82 and a debt-to-equity ratio of 2.45. The firm has a 50-day moving average price of $155.96 and a 200-day moving average price of $170.53. IQVIA has a twelve month low of $134.65 and a twelve month high of $252.88.
Hedge Funds Weigh In On IQVIA
A hedge fund recently raised its stake in IQVIA stock. Brighton Jones LLC raised its stake in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 244.4% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,575 shares of the medical research company's stock after acquiring an additional 2,537 shares during the period. Brighton Jones LLC's holdings in IQVIA were worth $703,000 at the end of the most recent quarter. Institutional investors and hedge funds own 89.62% of the company's stock.
Analyst Upgrades and Downgrades
Several equities analysts have weighed in on IQV shares. HSBC lowered IQVIA from a "buy" rating to a "hold" rating and cut their target price for the company from $260.00 to $160.00 in a research note on Friday, April 25th. Redburn Partners set a $188.00 price target on IQVIA in a research report on Friday, May 23rd. Evercore ISI increased their price objective on IQVIA from $170.00 to $180.00 and gave the stock an "outperform" rating in a report on Wednesday, July 9th. Hsbc Global Res downgraded IQVIA from a "strong-buy" rating to a "hold" rating in a report on Friday, April 25th. Finally, UBS Group raised their price target on IQVIA from $185.00 to $225.00 and gave the company a "buy" rating in a research note on Wednesday. Seven analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $226.95.
Read Our Latest Stock Report on IQVIA
About IQVIA
(
Get Free Report)
IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
Recommended Stories

Before you consider IQVIA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IQVIA wasn't on the list.
While IQVIA currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.